<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is no widely accepted standard for antifungal prophylaxis in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">Infectious Diseases</z:e> Working Party of the German Society for Haematology and <z:hpo ids='HP_0002664'>Oncology</z:hpo> assigned a committee of hematologists and <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious disease</z:e> specialists to develop recommendations </plain></SENT>
<SENT sid="2" pm="."><plain>Literature data bases were systematically searched for clinical trials on antifungal prophylaxis </plain></SENT>
<SENT sid="3" pm="."><plain>The studies identified were shared within the committee </plain></SENT>
<SENT sid="4" pm="."><plain>Data were extracted by two of the authors (OAC and MSi) </plain></SENT>
<SENT sid="5" pm="."><plain>The consensus process was conducted by email communication </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, a review committee discussed the proposed recommendations </plain></SENT>
<SENT sid="7" pm="."><plain>After consensus was established the recommendations were finalized </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 86 trials were identified including 16,922 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Only a few trials yielded significant differences in efficacy </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="2" ids="46081">Fluconazole</z:chebi> 400 mg/d improved the incidence rates of invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> and attributable mortality in allogeneic stem cell recipients </plain></SENT>
<SENT sid="11" pm="."><plain>Posaconazole 600 mg/d reduced the incidence of IFI and attributable mortality in allogeneic stem cell recipients with severe <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e>, and in patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> additionally reduced overall mortality </plain></SENT>
<SENT sid="12" pm="."><plain>Aerosolized <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> reduced the incidence rate of <z:e sem="disease" ids="C0276653" disease_type="Disease or Syndrome" abbrv="">invasive pulmonary aspergillosis</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Posaconazole 600 mg/d is recommended in patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or undergoing allogeneic stem cell recipients with <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> for the prevention of invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> and attributable mortality (Level A I) </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="2" ids="46081">Fluconazole</z:chebi> 400 mg/d is recommended in allogeneic stem cell recipients until development of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> only (Level A I) </plain></SENT>
<SENT sid="15" pm="."><plain>Aerosolized <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> is recommended during prolonged <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (Level B II) </plain></SENT>
</text></document>